Literature DB >> 26783127

Rationale for Using of Bifidobacterium Probiotic Strains-Fermented Milk Against Colitis Based on Animal Experiments and Clinical Trials.

Akemi Imaoka1, Yoshinori Umesaki2.   

Abstract

Probiotic foods such as probiotic strain-fermented milk or supplements proposing various health claims are now available. The beneficial effects of these probiotic foods on the digestive system are expected for not only healthy persons but also patients with diseases of the alimentary tract. This review focused on the rationale of using our Bifidobacterium strains-fermented milk as an adjunct for the prevention of recurrence or exacerbation of colitis. Animal experiments using gnotobiotic colitis or spontaneously colitis models and also human clinical trials of ulcerative colitis patients showed the potential of Bifidobacterium strains-fermented milk as a beneficial anti-colitis adjunct.

Entities:  

Keywords:  Bifidobacterium; Colitis; Fermented milk; Intestinal microbiota; Probiotics

Year:  2008        PMID: 26783127     DOI: 10.1007/s12602-008-9001-8

Source DB:  PubMed          Journal:  Probiotics Antimicrob Proteins        ISSN: 1867-1306            Impact factor:   4.609


  31 in total

Review 1.  Structure of the intestinal flora responsible for development of the gut immune system in a rodent model.

Authors:  Y Umesaki; H Setoyama
Journal:  Microbes Infect       Date:  2000-09       Impact factor: 2.700

2.  Mucosal blood flow and generation of superoxide in rat experimental colitis induced by succinic acid.

Authors:  S Fukui; T Shimoyama; K Tamura; M Yamamura; M Satomi
Journal:  J Gastroenterol       Date:  1997-08       Impact factor: 7.527

3.  Early administration of Bifidobacterium breve to preterm infants: randomised controlled trial.

Authors:  H Kitajima; Y Sumida; R Tanaka; N Yuki; H Takayama; M Fujimura
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  1997-03       Impact factor: 5.747

4.  Lamina propria and circulating interleukin-8 in newly and previously diagnosed pediatric inflammatory bowel disease patients.

Authors:  Krishna P Reddy; Jonathan E Markowitz; Eduardo D Ruchelli; Robert N Baldassano; Kurt A Brown
Journal:  Dig Dis Sci       Date:  2007-01-12       Impact factor: 3.199

5.  Abrupt induction of GDP-fucose: asialo GM1 fucosyltransferase in the small intestine after conventionalization of germ-free mice.

Authors:  Y Umesaki; T Sakata; T Yajima
Journal:  Biochem Biophys Res Commun       Date:  1982-03-30       Impact factor: 3.575

Review 6.  Lessons from genetically engineered animal models. XII. IL-10-deficient (IL-10(-/-) mice and intestinal inflammation.

Authors:  D M Rennick; M M Fort
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2000-06       Impact factor: 4.052

7.  Systemic antibodies towards mucosal bacteria in ulcerative colitis and Crohn's disease differentially activate the innate immune response.

Authors:  E Furrie; S Macfarlane; J H Cummings; G T Macfarlane
Journal:  Gut       Date:  2004-01       Impact factor: 23.059

8.  Interleukin-10-deficient mice develop chronic enterocolitis.

Authors:  R Kühn; J Löhler; D Rennick; K Rajewsky; W Müller
Journal:  Cell       Date:  1993-10-22       Impact factor: 41.582

9.  A microbial symbiosis factor prevents intestinal inflammatory disease.

Authors:  Sarkis K Mazmanian; June L Round; Dennis L Kasper
Journal:  Nature       Date:  2008-05-29       Impact factor: 49.962

10.  Randomized controlled trial of the effect of bifidobacteria-fermented milk on ulcerative colitis.

Authors:  Hideki Ishikawa; Ikuko Akedo; Yoshinori Umesaki; Ryuichiro Tanaka; Akemi Imaoka; Toru Otani
Journal:  J Am Coll Nutr       Date:  2003-02       Impact factor: 3.169

View more
  1 in total

1.  Effect of Milk Fermented with Lactobacillus fermentum on the Inflammatory Response in Mice.

Authors:  Lourdes Santiago-López; Adrián Hernández-Mendoza; Verónica Mata-Haro; Belinda Vallejo-Córdoba; Abraham Wall-Medrano; Humberto Astiazarán-García; María Del Carmen Estrada-Montoya; Aarón F González-Córdova
Journal:  Nutrients       Date:  2018-08-08       Impact factor: 5.717

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.